Literature DB >> 17118420

Effect of exogenous interferon and an interferon inducer on western equine encephalitis virus disease in a hamster model.

Justin G Julander1, Venkatraman Siddharthan, Lawrence M Blatt, Kristiina Schafer, Robert W Sidwell, John D Morrey.   

Abstract

Mice are used as models for western equine encephalitis virus (WEEV) infection, but high mortality is generally only seen with intracranial or intranasal challenge, while peripheral inoculation results in approximately 50% mortality and is not dose-dependent. Hamsters were therefore studied as a model for WEEV infection. Hamsters were highly sensitive to intraperitoneal (i.p.) infection with WEEV. Disease progression was rapid, and virus titers in serum, brain, liver, and kidney of infected hamsters peaked between 2 and 4 days post-virus inoculation (dpi). Foci of virus infection were detected in neurons of the cerebral cortex and midbrain. Pre-treatment i.p. with either interferon alfacon-1 (5 microg/kg/day) or with Ampligen (3.2 mg/kg/day) resulted in complete survival, reduced brain titers, and improved weight gain. This model of WEEV infection in hamsters appears to serve as a suitable model for the evaluation of potential therapeutic agents for the treatment of WEE disease.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17118420      PMCID: PMC2040270          DOI: 10.1016/j.virol.2006.10.031

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  41 in total

1.  Mismatched double-stranded RNA (polyI-polyC(12)U) is synergistic with multiple anti-HIV drugs and is active against drug-sensitive and drug-resistant HIV-1 in vitro.

Authors:  R J Essey; B R McDougall; W E Robinson
Journal:  Antiviral Res       Date:  2001-09       Impact factor: 5.970

2.  Attenuated variants of eastern equine encephalomyelitis virus: pathomorphological, immunofluorescence and virological studies of infection in Syrian hamsters.

Authors:  D P Dremov; R G Solyanik; T L Miryutova; L M Laptakova
Journal:  Acta Virol       Date:  1978-03       Impact factor: 1.162

3.  Experimental yellow fever virus infection in the Golden Hamster (Mesocricetus auratus). I. Virologic, biochemical, and immunologic studies.

Authors:  R B Tesh; H Guzman; A P da Rosa; P F Vasconcelos; L B Dias; J E Bunnell; H Zhang; S Y Xiao
Journal:  J Infect Dis       Date:  2001-04-17       Impact factor: 5.226

4.  Opsonization of alphaviruses in hamsters.

Authors:  P B Jahrling; R A Hesse; A O Anderson; J D Gangemi
Journal:  J Med Virol       Date:  1983       Impact factor: 2.327

5.  Interferon alfacon-1 protects hamsters from lethal pichinde virus infection.

Authors:  Brian B Gowen; Dale L Barnard; Donald F Smee; Min-Hui Wong; Anne M Pace; Kie-Hoon Jung; Scott G Winslow; Kevin W Bailey; Lawrence M Blatt; Robert W Sidwell
Journal:  Antimicrob Agents Chemother       Date:  2005-06       Impact factor: 5.191

6.  Interferon-alphaCon1 suppresses proliferation of liver cancer cell lines in vitro and in vivo.

Authors:  Toru Hisaka; Hirohisa Yano; Sachiko Ogasawara; Seiya Momosaki; Naoyo Nishida; Yumi Takemoto; Sakiko Kojiro; Yuno Katafuchi; Masamichi Kojiro
Journal:  J Hepatol       Date:  2004-11       Impact factor: 25.083

7.  Efficacy of DNA vaccination against western equine encephalitis virus infection.

Authors:  Les P Nagata; Wei-Gang Hu; Saad A Masri; George A Rayner; Fay L Schmaltz; Dipankar Das; Josh Wu; Melissa C Long; Christine Chan; David Proll; Scott Jager; Lellean Jebailey; Mavanur R Suresh; Jonathan P Wong
Journal:  Vaccine       Date:  2005-03-18       Impact factor: 3.641

8.  The pathogenesis of western equine encephalitis virus (W.E.E.) in adult hamsters with special reference to the long and short term effects on the C.N.S. of the attenuated clone 15 variant.

Authors:  I Zlotnik; S Peacock; D P Grant; D Batter-Hatton
Journal:  Br J Exp Pathol       Date:  1972-02

9.  A Phase I/II study evaluating escalating doses of recombinant human albumin-interferon-alpha fusion protein in chronic hepatitis C patients who have failed previous interferon-alpha-based therapy.

Authors:  Vijayan Balan; David R Nelson; Mark S Sulkowski; Gregory T Everson; Louis R Lambiase; Rusell H Wiesner; Rolland C Dickson; Anthony B Post; Robert R Redfield; Gary L Davis; Avidan U Neumann; Blaire L Osborn; William W Freimuth; G Mani Subramanian
Journal:  Antivir Ther       Date:  2006

10.  Effect of interferon-alpha and interferon-inducers on West Nile virus in mouse and hamster animal models.

Authors:  John D Morrey; Craig W Day; Justin G Julander; Lawrence M Blatt; Donald F Smee; Robert W Sidwell
Journal:  Antivir Chem Chemother       Date:  2004-03
View more
  13 in total

1.  Treatment with cationic liposome-DNA complexes (CLDCs) protects mice from lethal Western equine encephalitis virus (WEEV) challenge.

Authors:  Christopher H Logue; Aaron T Phillips; Eric C Mossel; Jeremy P Ledermann; Thomas Welte; Steve W Dow; Ken E Olson; Ann M Powers
Journal:  Antiviral Res       Date:  2010-05-07       Impact factor: 5.970

2.  Manipulation of host factors optimizes the pathogenesis of western equine encephalitis virus infections in mice for antiviral drug development.

Authors:  Pennelope K Blakely; Phillip C Delekta; David J Miller; David N Irani
Journal:  J Neurovirol       Date:  2014-11-01       Impact factor: 2.643

3.  Immunopathogenesis of alphaviruses.

Authors:  Victoria K Baxter; Mark T Heise
Journal:  Adv Virus Res       Date:  2020-07-08       Impact factor: 9.937

4.  Liposome-antigen-nucleic acid complexes protect mice from lethal challenge with western and eastern equine encephalitis viruses.

Authors:  Aaron T Phillips; Tony Schountz; Ann M Toth; Amber B Rico; Donald L Jarvis; Ann M Powers; Ken E Olson
Journal:  J Virol       Date:  2013-11-20       Impact factor: 5.103

Review 5.  Encephalitic alphaviruses.

Authors:  Michele A Zacks; Slobodan Paessler
Journal:  Vet Microbiol       Date:  2009-08-28       Impact factor: 3.293

6.  Virulence variation among isolates of western equine encephalitis virus in an outbred mouse model.

Authors:  Christopher H Logue; Christopher F Bosio; Thomas Welte; Kimberley M Keene; Jeremy P Ledermann; Aaron Phillips; Brian J Sheahan; Dennis J Pierro; Nicole Marlenee; Aaron C Brault; Catharine M Bosio; Amber J Singh; Ann M Powers; Ken E Olson
Journal:  J Gen Virol       Date:  2009-04-29       Impact factor: 3.891

7.  Effect of T-705 treatment on western equine encephalitis in a mouse model.

Authors:  Justin G Julander; Donald F Smee; John D Morrey; Yousuke Furuta
Journal:  Antiviral Res       Date:  2009-03-10       Impact factor: 5.970

8.  C3H/HeN mouse model for the evaluation of antiviral agents for the treatment of Venezuelan equine encephalitis virus infection.

Authors:  Justin G Julander; Ramona Skirpstunas; Venkatraman Siddharthan; Kristiina Shafer; Justin D Hoopes; Donald F Smee; John D Morrey
Journal:  Antiviral Res       Date:  2008-02-13       Impact factor: 5.970

9.  Susceptibility and Lethality of Western Equine Encephalitis Virus in Balb/c Mice When Infected by the Aerosol Route.

Authors:  Amanda L Phelps; Lyn M O'Brien; Lin S Eastaugh; Carwyn Davies; Mark S Lever; Jane Ennis; Larry Zeitlin; Alejandro Nunez; David O Ulaeto
Journal:  Viruses       Date:  2017-06-27       Impact factor: 5.048

10.  Bioluminescent imaging and histopathologic characterization of WEEV neuroinvasion in outbred CD-1 mice.

Authors:  Aaron T Phillips; Charles B Stauft; Tawfik A Aboellail; Ann M Toth; Donald L Jarvis; Ann M Powers; Ken E Olson
Journal:  PLoS One       Date:  2013-01-02       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.